TY - JOUR T1 - Long-term echocardiographic changes with positive airway pressure therapy in obesity hypoventilation syndrome JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.2998 VL - 56 IS - suppl 64 SP - 2998 AU - Mª Ángeles Sanchez Quiroga AU - Juan Fernando Masa Jiménez AU - Babak Mohklesi AU - Ivan Benitez AU - Maria Victoria Mogollón AU - Francisco Javier Gómez De Terreros AU - Auxiliadora Romero AU - Candela Caballero Eraso AU - María Luz Alonso Álvarez AU - Estrella Ordax Carballo AU - Teresa Gómez García AU - Mónica González AU - Soledad López Martín AU - José María Marín AU - Sergi Marti AU - Trinidad Diaz Cambriles AU - Eusebi Chiner AU - Carlos Egea AU - Javier Barca AU - Francisco José Vázquez Polo AU - Miguel Angel Negrin AU - María Martel Escobar AU - Jaime Corral Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/2998.abstract N2 - Rationale: Obesity hypoventilation syndrome (OHS) has been associated with cardiac dysfunction. However, randomized trials have assessing the impact of long-term noninvasive ventilation (NIV) or CPAP on cardiac structure and function assessed by echocardiography are lacking.Methods: In a pre-specified secondary analysis of the largest multicenter randomized controlled trial of OHS〔Pickwick project, n=221 patient with OHS and coexistent severe obstructive sleep apnea (OSA)〕, we compared the effectiveness of 3 years of NIV and CPAP on structural and functional echocardiographic changes.At baseline and annually during 3 sequential years patients underwent transthoracic two-dimensional and doppler echocardiography. Echocardiographers were blinded to the treatment allocation. Statistical analysis was performed using a linear mixed-effects model with a treatment group/repeated measures interaction to determine the differential effect between CPAP and NIV.Results: 196 patients were analyzed, 102 treated with CPAP and 94 treated with NIV. Systolic pulmonary artery pressure decreased from 40.5±1.47 mmHg at baseline to 35.3±1.33 mmHg at 3 years with CPAP and from 41.5±1.56 mmHg to 35.5±1.42 with NIV (p<0.0001 for longitudinal intragroup changes for both treatment arms). However, there were no significant differences between groups (Mean (SE) NIV-CPAP differences: 0.205 (1.955), p=0.917). NIV and CPAP therapies similarly improved left ventricular diastolic dysfunction (LVDF) and reduced left atrial diameter.Conclusion: In patients with OHS and concomitant severe OSA, long-term treatment with NIV and CPAP led to similar degrees of improvement in pulmonary hypertension and LVDF.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2998.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -